Diagnosis and treatment of ADHD in pediatric patients during the first year of elexacaftor/tezacaftor/ivacaftor

Documenti analoghi

• Medication utilization and lung function changes after initiation of treatment with elexacaftor/tezacaftor/ivacaftor
  di: Richard De Vuyst, et al.
  Pubblicazione: (2024)
• Disparities in elexacaftor/tezacaftor/ivacaftor initiation in the US cystic fibrosis population
  di: Kamyron Jordan, et al.
  Pubblicazione: (2024)
• Severe mental health changes in patients with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor therapy
  di: Cameron J. McKinzie, et al.
  Pubblicazione: (2024)
• Mental health, sleep, and respiratory health after initiating elexacaftor/tezacaftor/ivacaftor treatment in children with cystic fibrosis
  di: Hiep Pham, et al.
  Pubblicazione: (2024)
• Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor treatment in children aged 6‐11 years with cystic fibrosis in a real‐world setting
  di: Valeria Daccò, et al.
  Pubblicazione: (2024)